News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Lowell Hart

Articles by Lowell Hart

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

ByLowell Hart,Seock-Ah Im,Sara M. Tolaney, MD, MPH,Mario Campone,Timothy Pluard,Berta Sousa,Gilles Freyer,Thomas Decker,Kevin Kalinsky, MD, MS,Astrid Thuerigen,Melissa Gao,Huilin Hu,Sherko Kümmel

August 9th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i